Neuromodulation

Elliot S. Krames, MD, is a board-certified anesthesiologist who has been practicing pain medicine solely since 1987. He is a worldwide-recognized leader and educator in the field of neuromodulation for pain control. He has written extensively on implantable technologies for pain management and has conducted national and international symposia related to this topic. He is co-founder of the National Pain Foundation, a founding member of the North American Neuromodulation Society and has participated on the boards of the North American Neuromodulation Society, the International Neuromodulation Society, the World Institute of Pain, the American Academy of Pain Medicine, and the American Board of Pain Medicine. Dr. Krames has published more than 100 research papers, serves on several editorial boards, and co-edited a number of books. Dr. Krames was the founding editor of Neuromodulation: Technology at the Neural Interface, the journal of the International Neuromodulation Society, serving as Editor-in-Chief from 1998 until September 2009, when he became Emeritus Editor-in-Chief. Dr. Krames served as INS President from 2006 to 2009, as immediate Past President from 2009 to 2011, and since 2011 has been Emeritus Director-at-Large. Dr. Peckham is the Donnell Institute Professor of Biomedical Engineering and Orthopaedics at Case Western Reserve University and Director, Cleveland Functional Electrical Stimulation Center. The major area of Dr. Peckham's research is in rehabilitation engineering and neuroprostheses. He’s also the Founder for the Institute for Functional Restoration at the Case Western School of Medicine and the Co-Director of MetroHealth Rehabilitation Institute of Ohio. A holder of eight patents, he is a member of multiple councils, Dr. Peckham is also a fellow of the American Institute of Medical and Biological Engineering. Dr. Rezai is currently executive chair and vice president of neurosciences for WVU Medicine. He also serves as associate dean and the John D. Rockefeller IV tenured professor in neurosciences at the WVU School of Medicine. Dr. Rezai has published over 150 peer reviewed articles, more than 30 book chapters, and serves on the editorial board of five journals. Dr. Rezai is currently the Past President of the Congress of Neurological Surgeons (CNS), the largest neurosurgical societies in the world, as well as the Past President North American Neuromodulation Society (NANS), and the American Society of Stereotactic and Functional Neurosurgery (ASSFN).Dr. Rezai’s research focuses on mechanisms of neurostimulation, and developing neuromodulation devices and novel therapeutic strategies for treatment of neurological disorders.

VOLUME 1 SECTION I: DEFINING NEUROMODULATION SECTION II: THE BRAIN INITIATIVE—IMPLICATIONS FOR A REVOLUTIONARY CHANGE IN CLINICAL MEDICINE VIA NEUROMODULATION TECHNOLOGY SECTION III: FUNDAMENTALS AND MECHANISMS OF NEUROMODULATION SECTION IV: TECHNOLOGY AND DEVICES SECTION V: BRAIN, COMPUTER AND MACHINE INTERFACING SECTION VI: EMERGING TECHNOLOGIES AND TECHNIQUES SECTION VII: SURGICAL PROCEDURES AND TECHNIQUES

VOLUME 2 SECTION VIII: NEUROMODULATION FOR PAIN CONTROL SECTION VIII A: SPINAL CORD STIMULATION FOR PAIN CONTROL SECTION VIII B: PERIPHERAL NERVE STIMULATION FOR PAIN CONTROL INTRODUCTION: PERIPHERAL NERVE STIMULATION FOR PAIN CONTROL SECTION VIII C: INTRATHECAL THERAPIES FOR PAIN CONTROL AND THE CONTROL OF SPASTICITY SECTION VIII D: INTRACRANIAL PROCEDURES FOR CHRONIC PAIN SECTION IX: NEUROMODULATION FOR MOVEMENT DISORDERS SECTION X: NEUROSTIMULATION FOR EPILEPSY SECTION XI: NEUROMODULATION FOR BEHAVIORAL AND COGNITIVE DISORDERS

VOLUME 3 SECTION XII: NEUROMODULATION FOR FUNCTIONAL RESTORATION SECTION XIII: NEUROMODULATION FOR ORGAN SYSTEMS SECTION XIII A: NEUROMODULATION FOR CARDIOVASCULAR DISORDERS SECTION XIII B: NEUROMODULATION FOR PULMONARY DISORDERS SECTION XIII C: NEUROMODULATION FOR GASTROINTESTINAL DISORDERS SECTION XIII D: NEUROMODULATION FOR UROGENITAL DISORDERS SECTION XIV: NEUROMODULATION FOR ENDOCRINE, IMMUNE, AND INFLAMMATORY DISORDERS SECTION XV: NON INVASIVE NEUROMODULATION SECTION XVI: THE BUSINESS END OF NEUROMODULATION